| 1.29 0.06 (4.88%) | 10-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.78  |
1-year : | 2.08 |
| Resists | First : | 1.52 |
Second : | 1.78 |
| Pivot price | 1.24 |
|||
| Supports | First : | 1.19 |
Second : | 0.99 |
| MAs | MA(5) : | 1.29  |
MA(20) : | 1.21 |
| MA(100) : | 0.99 |
MA(250) : | 1.01 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 41.6 |
D(3) : | 44.7 |
| RSI | RSI(14): 58.4 |
|||
| 52-week | High : | 1.77 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ESLA ] has closed below upper band by 35.0%. Bollinger Bands are 53.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.24 - 1.24 | 1.24 - 1.25 |
| Close: | 1.28 - 1.29 | 1.29 - 1.3 |
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Mon, 06 Oct 2025
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Business Wire
Fri, 26 Sep 2025
Estrella Immunopharma appoints Jia Dengyao to board of directors By Investing.com - Investing.com Nigeria
Sun, 17 Aug 2025
Is Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Invest In Growth? - simplywall.st
Thu, 05 Jun 2025
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - Business Wire
Tue, 03 Jun 2025
Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com Canada
Tue, 03 Jun 2025
ESLA’s Latest Gains: What’s Behind the Surge? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 37 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 70.3 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 140 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -5.38 |
| PEG Ratio | 0 |
| Price to Book value | -8.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|